Shares of Quest Diagnostics Incorporated (NYSE:DGX) have received a consensus recommendation of “Hold” from the twenty-three ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $104.81.
A number of equities analysts have commented on DGX shares. KeyCorp restated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Wells Fargo & Company lowered their price target on shares of Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research note on Friday, October 20th. Zacks Investment Research cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Goldman Sachs Group, Inc. (The) cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price target for the stock from $121.00 to $113.00 in a research note on Tuesday, October 10th.
In related news, Chairman Stephen H. Rusckowski sold 2,525 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $108.03, for a total value of $272,775.75. Following the transaction, the chairman now owns 168,413 shares in the company, valued at $18,193,656.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen H. Rusckowski sold 53,933 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $108.16, for a total transaction of $5,833,393.28. Following the completion of the transaction, the chief executive officer now owns 220,049 shares in the company, valued at approximately $23,800,499.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,396 shares of company stock worth $17,343,852. Insiders own 1.75% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. WFG Advisors LP raised its holdings in Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after buying an additional 301 shares during the period. Sun Life Financial INC grew its position in Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after acquiring an additional 990 shares in the last quarter. Parallel Advisors LLC grew its position in Quest Diagnostics by 0.9% in the second quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 12 shares in the last quarter. Acrospire Investment Management LLC grew its position in Quest Diagnostics by 300.0% in the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Quest Diagnostics in the second quarter valued at approximately $180,000. Hedge funds and other institutional investors own 88.52% of the company’s stock.
Quest Diagnostics (DGX) traded up $0.05 during mid-day trading on Thursday, reaching $92.46. 1,328,456 shares of the company traded hands, compared to its average volume of 991,715. Quest Diagnostics has a 1 year low of $86.11 and a 1 year high of $112.96. The stock has a market cap of $12,600.00, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 1.94 and a beta of 0.59. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.37 and a current ratio of 1.47.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. Quest Diagnostics’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.37 EPS. research analysts anticipate that Quest Diagnostics will post 5.65 EPS for the current year.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.